Search Result

Results for "

capecitabine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) DNA/RNA Synthesis (7) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (4) Gap Junction Protein (2) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (6) Reference Standards (1) STAT (1)
By Research Areas:	Cancer (14) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0016

*Capecitabine* 20+ Cited Publications	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.

HY-B0016S

Capecitabine-d11	Isotope-Labeled Compounds DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Capecitabine-d₁₁ is the deuterium labeled Capecitabine. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase .

HY-B0016R

Capecitabine (Standard)	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Capecitabine (Standard) is the analytical standard of Capecitabine. This product is intended for research and analytical applications. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.

HY-W099488

Capecitabine 2',3'-diacetate	Drug Intermediate	Cancer
Capecitabine 2',3'-diacetate (Compound 10b) is the prodrug for the antitumor agent Capecitabine (HY-B0016) .

HY-14905

Uridine triacetate Tri-O-acetyl uridine	Others	Neurological Disease
Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .

HY-134554

5′-Deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine	Drug Derivative	Cancer
5′-Deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine is an impurity in the synthesis of Capecitabine (HY-B0016) .

HY-W009538

5'-Deoxy-5-fluorocytidine 5-Fluoro-5'-deoxycytidine	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Drug Metabolite	Cancer
5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W614957R

Capecitabine-2',3'-cyclic carbonate (Standard)	Drug Derivative	Cancer
Capecitabine-2',3'-cyclic carbonate (Standard) is the analytical standard of Capecitabine-2',3'-cyclic carbonate. This product is intended for research and analytical applications. Capecitabine-2',3'-cyclic carbonate (Compd 5a) is a 5'-deoxy-5-fluorocytidine derivative with anticancer activity .

HY-W614957

Capecitabine-2',3'-cyclic carbonate	Drug Derivative	Cancer
Capecitabine-2',3'-cyclic carbonate (Compd 5a) is a 5'-deoxy-5-fluorocytidine derivative with anticancer activity .

HY-P9991A

Osemitamab (FUT8-KO)	Gap Junction Protein	Cancer
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-W009538R

5'-Deoxy-5-fluorocytidine (Standard) 5-Fluoro-5'-deoxycytidine (Standard)	Nucleoside Antimetabolite/Analog Reference Standards DNA/RNA Synthesis Drug Metabolite	Cancer
5'-Deoxy-5-fluorocytidine (Standard) is the analytical standard of 5'-Deoxy-5-fluorocytidine (HY-W009538). This product is intended for research and analytical applications. 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W009538S

5'-Deoxy-5-fluorocytidine-d3 5-Fluoro-5'-deoxycytidine-d₃	Nucleoside Antimetabolite/Analog Isotope-Labeled Compounds DNA/RNA Synthesis Drug Metabolite	Cancer
5'-Deoxy-5-fluorocytidine-d₃ is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W009538S1

5'-Deoxy-5-fluorocytidine-13C5 5-Fluoro-5'-deoxycytidine-¹³C₅	Isotope-Labeled Compounds DNA/RNA Synthesis Drug Metabolite	Cancer
5'-Deoxy-5-fluorocytidine-13C5 is the ¹³C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-P9991

Osemitamab TST001	Gap Junction Protein	Cancer
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-168519

STAT3-IN-36	STAT	Cancer
STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC₅₀ 1.8 μM. .

Cat. No.	Product Name	Target	Research Area

HY-P9991

Osemitamab TST001	Gap Junction Protein	Cancer
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-P9991A

Osemitamab (FUT8-KO)	Gap Junction Protein	Cancer
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

Cat. No.	Product Name	Chemical Structure

HY-B0016S

Capecitabine-d11
Capecitabine-d₁₁ is the deuterium labeled Capecitabine. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase .

HY-W009538S

5'-Deoxy-5-fluorocytidine-d3
5'-Deoxy-5-fluorocytidine-d₃ is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

5'-Deoxy-5-fluorocytidine-d3

5'-Deoxy-5-fluorocytidine-d₃ is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W009538S1

5'-Deoxy-5-fluorocytidine-13C5
5'-Deoxy-5-fluorocytidine-13C5 is the ¹³C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

5'-Deoxy-5-fluorocytidine-13C5

5'-Deoxy-5-fluorocytidine-13C5 is the ¹³C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.